Absorption, metabolism, and excretion of [14C]MK-0524, a prostaglandin D2 receptor antagonist, in humans

Drug Metabolism and Disposition

Volumn 35, Issue 7, 2007, Pages 1196-1202

  Karanam, Bindhu ^a   Madeira, Maria ^a   Bradley, Scott ^a   Wenning, Larissa ^a   Desai, Rajesh ^a   Soli, Eric ^a   Schenk, David ^a   Jones, Allen ^a   Dean, Brian ^a   Doss, George ^a   Garrett, Graigory ^a   Crumley, Tami ^a   Nirula, Ajay ^a   Lai, Eseng ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[4 (4 CHLOROBENZYL) 7 FLUORO 5 (METHYLSULFONYL) 1,2,3,4 TETRAHYDROCYCLOPENTAINDOL 3 YL]ACETIC ACID C 14; DRUG METABOLITE; GLUCURONIC ACID; MK 0524; PROSTAGLANDIN D2 RECEPTOR 1 ANTAGONIST; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; UREA;

ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG EXCRETION; DRUG METABOLISM; FECES; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RADIOACTIVITY; URINARY EXCRETION;

ADMINISTRATION, ORAL; BILE; BIOTRANSFORMATION; CARBON RADIOISOTOPES; FECES; GLUCURONIDES; HUMANS; HYDROXYLATION; INDOLES; INTESTINAL ABSORPTION; MALE; MOLECULAR STRUCTURE; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; REFERENCE VALUES;

EID: 34250713349     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.014696     Document Type: Article

References (13)

1. Bailey MJ and Dickinson RG (2003) Acyl glucuronide reactivity in perspective: biological consequences. Chem Biol Interact 145:117-137.
2. 2 receptor 1 antagonist, in rats, dogs and monkeys. Xenobiotica in press.
3. 2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A 103:6682-6687.
4. 2 receptor 1 antagonist, in microsomes and hepatocytes from preclinical species and humans. Drug Metab Dispos 35:293-292.
5. Koster A, Frankhuijzen-Sierevogel AC, and Noordhoek J (1985) Distribution of glucuronidation capacity (1-naphthol and morphine) along the rat intestine. Biochem Pharmacol 34:3527-3532.
6. Knopp RH (1999) Drug treatment of lipid disorders. N Engl J Med 341:498-511.
7. 2 (DP) antagonist MK-0524 and synthesis of metabolites. Bioorg Med Chem Lett 17:301-304.
8. Rubenfire M (2004) Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspeciality on Patient Compliance to Treatment (IMPACT) Study. Am J Cardiol 94:306-311.
9. Schwartz M, Desai R, Bi S, Miller A, and Matuszewski B (2006) Determination of a prostaglandin D2 antagonist and its acyl glucuronide metabolite in human plasma by high performance liquid chromatography with tandem mass spectrometric detection - a lack of MS/MS selectivity between a glucuronide conjugate and a phase I metabolite. J Chromatogr B 837:116-124.
10. Shepherd J, Packard DJ, Patsch JR, Gotto AM Jr, and Taunton OD (1979) Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoptotein A metabolism. J Clin Invest 63:858-867.
11. 2 receptor antagonist [(3R)-4-(4-chlorobenzyl)-7-fluoro-5- (methylsulfonyl)-1,2,3,4-tetrahydrocyclopentaindol-3-yl]-acetic acid (MK-0524). J Med Chem 50:794-806.
12. Vogt A, Kassner U, Hostalek U, Steinhagen-Thiessen E; NAUTILUS Study Group (2006) Evaluations of safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS Study. Curr Med Res Opin 22:417-425.
13. Zhao X-Q, Morse JS, Dowdy AA, Heise N, DeAngelis D, Frohlich J, Chait A, Albers JJ, and Brown BG (2004) Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). Am J Cardiol 93:307-312.